Clinical Trial of Electroacupuncture in Axial Spondyloarthritis (E-AcuSpA)

Not Applicable

Recruiting

• Conditions: Spondylarthritis; Axial Spondyloarthritis
• Interventions: Other: Electroacupuncture; Other: Manual acupuncture

• Registration Number: NCT04519866
• Lead Sponsor: Singapore General Hospital

Brief Summary

Axial spondyloarthritis (AxSpA) is a chronic disease that causes severe disability and poor quality of life. Current treatment options are limited and there are still significant non-responders to current western medications. Manual acupuncture has been shown to reduce pain in patients with AxSpA. There have been reports of electroacupuncture demonstrating more sustained pain relief. Therefore, the investigators aim to determine the clinical effectiveness, safety and cost-effectiveness of electroacupuncture as compared to manual acupuncture for patients with AxSpA through a randomized controlled trial.

Detailed Description

Patients with active axial spondyloarthritis despite non-steroidal anti-inflammatory drugs (NSAIDs) or biologics, will be randomly allocated to receive electroacupuncture or manual acupuncture on a 1:1 basis via random permuted block randomization. All patients will receive their standard of care (drug therapy and physiotherapy) as background therapy. This study will not be investigating any therapeutic or medicinal products (drugs).

Primary outcome would be the mean difference in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score between the 2 groups over 12 weeks (as assessed at weeks 0, 3, 6, 9, 12) adjusted for baseline covariate and other potential confounders. Patients will be followed up for BASDAI, other clinical, quality of life (QoL), economic outcomes as well as Traditional Chinese Medicine (TCM) syndrome scores over time for secondary and exploratory outcomes. A cost-effectiveness analysis will be performed. Adverse events will be recorded.

The primary hypothesis is that electroacupuncture may result in better disease activity control in patients with AxSpA as compared to manual acupuncture over 12 weeks, while secondary hypothesis is that electroacupuncture may result in greater improvements in other clinical and quality of life outcomes as compared to those receiving manual acupuncture over 24 weeks. The investigators also hypothesize that there is no difference in safety between both arms.

Study Timeline

• Study First Submitted: 2020-08-17
• Study First Submitted QC: 2020-08-17
• Study First Posted: 2020-08-20
• Study Start: 2021-02-24
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-19
• Last Update Posted: 2023-12-26
• Primary Completion: 2024-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Aged 21 years of age or older
• Diagnosed with AxSpA according to the 2009 Assessment of Spondyloarthritis International Society (ASAS) criteria
• Bath AS Disease Activity Index (BASDAI) score ≥4 on a 11-point Numerical Rating Scale (NRS)
• Failed 2 sequential NSAIDs (including cyclooxygenase-2 inhibitor) at maximal tolerated doses for ≥4 weeks in total
• Patients on concomitant biological therapy (e.g. tumour necrosis factor inhibitor therapy, anti-interleukin 17) or non-biologic disease-modifying antirheumatic drugs (DMARDs) (e.g. methotrexate (MTX) or sulfasalazine (SSZ) or leflunomide (LEF)) at study entry must be on the drug for ≥12 weeks and at stable dose for ≥4 weeks prior to randomisation
• Patients taking systemic corticosteroids have to be on stable dose of ≤10mg/day prednisolone or equivalent for at least two weeks before randomisation.

Exclusion Criteria

• Pregnant or breastfeeding women
• With bleeding disorders
• With blood-borne communicable diseases (e.g. hepatitis B, hepatitis C, human immunodeficiency virus, etc)
• With implantable electrical device (e.g. pacemaker)
• Suffering from impaired skin sensation or serious skin lesions along the vertebrae

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Electroacupuncture	Electroacupuncture	In addition to usual rheumatological care, patients in the electroacupuncture arm will undergo 2 courses of electroacupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
Manual acupuncture	Manual acupuncture	In addition to usual rheumatological care, patients in the manual acupuncture arm will undergo 2 courses of manual acupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.

Primary Outcome Measures

Name	Time	Method
Mean difference in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score between both groups	Week 3, 6, 9, 12	Mean difference in BASDAI score between both groups from baseline to weeks 3, 6, 9 and 12.; BASDAI score ranges from 0-10, with higher scores indicating higher disease activity.

Secondary Outcome Measures

Name	Time	Method
Mean difference in healthcare costs between both groups	Week 6, 12, 24	Mean difference in healthcare costs will be assessed for both groups at weeks 6, 12 and 24.
Mean difference in Assessment of Spondyloarthritis International Society Health Index (ASAS HI) score between both groups	Week 6, 12, 24	Mean difference in ASAS HI score between both groups from baseline to weeks 6, 12 and 24.; ASAS HI score ranges from 0-17, with higher scores indicating poorer health status.
Mean difference in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score between both groups	Week 24	Mean difference in BASDAI score between both groups from baseline to week 24. BASDAI score ranges from 0-10, with higher scores indicating higher disease activity.
Mean difference in Bath Ankylosing Spondylitis Functional Index (BASFI) score between both groups	Week 6, 12, 24	Mean difference in BASFI score between both groups from baseline to weeks 6, 12 and 24.; BASFI score ranges from 0-10, with higher scores indicating poorer functioning.
Mean difference in Ankylosing Spondylitis Quality of Life (ASQoL) score between both groups	Week 6, 12, 24	Mean difference in ASQoL score between both groups from baseline to weeks 6, 12 and 24.; ASQoL score ranges from 0-18, with higher scores indicating worse quality of life.
Mean difference in EuroQol- 5 Dimension (EQ-5D) score between both groups	Week 6, 12, 24	Mean difference in EQ-5D score between both groups from baseline to weeks 6, 12 and 24.; EQ-5D consists of a descriptive system and a visual analogue scale. The descriptive system covers 5 dimensions: mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression. Each dimension has a minimum and maximum score of 1 and 5 respectively, with higher scores representing a greater problem in that dimension. The visual analogue scale ranges from 0-100, with lower scores indicating poorer health status.
Mean difference in Work Productivity and Activity Impairment (WPAI) score between both groups	Week 6, 12, 24	Mean difference in WPAI score between both groups from baseline to weeks 6, 12 and 24.; WPAI measures absenteeism, presenteeism, work productivity loss and activity impairment. These are expressed as percentages, from 0-100, with higher numbers indicating greater impairment and less productivity.
Mean difference in Bath Ankylosing Spondylitis Patient Global score (BAS-G) between both groups	Week 6, 12, 24	Mean difference in BAS-G score between both groups from baseline to weeks 6, 12 and 24.; BAS-G score ranges from 0-10, with higher scores reflecting poorer well-being.

Trial Locations

Locations (1)

Singapore General Hospital; 🇸🇬 Singapore, Singapore